Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells.
W Y Gao, … , S Broder, H Mitsuya
W Y Gao, … , S Broder, H Mitsuya
Published May 1, 1993
Citation Information: J Clin Invest. 1993;91(5):2326-2333. https://doi.org/10.1172/JCI116463.
View: Text | PDF
Research Article Article has an altmetric score of 9

Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells.

  • Text
  • PDF
Abstract

The antiviral activity of azidothymidine (AZT), dideoxycytidine (ddC), and dideoxyinosine (ddI) against HIV-1 was comparatively evaluated in PHA-stimulated PBM. The mean drug concentration which yielded 50% p24 Gag negative cultures were substantially different: 0.06, 0.2, and 6 microM for AZT, ddC, and ddI, respectively. We found that AZT was preferentially phosphorylated to its triphosphate (TP) form in PHA-PBM rather than unstimulated, resting PBM (R-PBM), producing 10- to 17-fold higher ratios of AZTTP/dTTP in PHA-PBM than in R-PBM. The phosphorylation of ddC and ddI to their TP forms was, however, much less efficient in PHA-PBM, resulting in approximately 5-fold and approximately 15-fold lower ratios of ddCTP/dCTP and ddATP/dATP, respectively, in PHA-PBM than in R-PBM. The comparative order of PHA-induced increase in cellular enzyme activities examined was: thymidine kinase > uridine kinase > deoxycytidine kinase > adenosine kinase > 5'-nucleotidase. We conclude that AZT, ddC, and ddI exert disproportionate antiviral effects depending on the activation state of the target cells, i.e., ddI and ddC exert antiviral activity more favorably in resting cells than in activated cells, while AZT preferentially protects activated cells against HIV infection. Considering that HIV-1 proviral DNA synthesis in resting lymphocytes is reportedly initiated at levels comparable with those of activated lymphocytes, the current data should have practical relevance in the design of anti-HIV chemotherapy, particularly combination chemotherapy.

Authors

W Y Gao, T Shirasaka, D G Johns, S Broder, H Mitsuya

×

Total citations by year

Year: 2024 2023 2022 2021 2020 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997 1996 1995 1994 1993 Total
Citations: 1 1 1 1 1 2 3 3 2 3 4 3 13 4 4 5 8 2 6 7 4 6 11 15 13 10 8 16 15 13 1 186
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article (186)

Title and authors Publication Year
The Phenomenon of Antiretroviral Drug Resistance in the Context of Human Immunodeficiency Virus Treatment: Dynamic and Ever Evolving Subject Matter
Apetroaei MM, Velescu BȘ, Nedea MI, Dinu-Pîrvu CE, Drăgănescu D, Fâcă AI, Udeanu DI, Arsene AL
Biomedicines 2024
Identification of SARS-CoV-2 M(pro) inhibitors containing P1' 4-fluorobenzothiazole moiety highly active against SARS-CoV-2.
Higashi-Kuwata N, Tsuji K, Hayashi H, Bulut H, Kiso M, Imai M, Ogata-Aoki H, Ishii T, Kobayakawa T, Nakano K, Takamune N, Kishimoto N, Hattori SI, Das D, Uemura Y, Shimizu Y, Aoki M, Hasegawa K, Suzuki S, Nishiyama A, Saruwatari J, Shimizu Y, Sukenaga Y, Takamatsu Y, Tsuchiya K, Maeda K, Yoshimura K, Iida S, Ozono S, Suzuki T, Okamura T, Misumi S, Kawaoka Y, Tamamura H, Mitsuya H
Nature Communications 2023
Genital immune cell activation and tenofovir gel efficacy in women at risk of HIV infection
Lenine Liebenberg, Jo-Ann Passmore, Farzana Osman, Janine Jewanraj, Andile Mtshali, J. Garcia-Lerma, Walid Heneine, Angela Holder, Derseree Archary, Sinaye Ngcapu, Aida Sivro, Leila Mansoor, Quarraisha Karim, Salim Karim, Lyle McKinnon
Clinical Infectious Diseases 2022
Non-structural protein 5 (NS5) as a target for antiviral development against established and emergent flaviviruses
PO Fernandes, MA Chagas, WR Rocha, AH Moraes
Current Opinion in Virology 2021
Intracellular Tenofovir and Emtricitabine Concentrations in Younger and Older Women with HIV Receiving Tenofovir Disoproxil Fumarate/Emtricitabine
JB Dumond, CP Bay, JA Nelson, A Davalos, A Edmonds, KD Paris, C Sykes, K Anastos, R Sharma, S Kassaye, B Tamraz, AL French, S Gange, I Ofotokun, MA Fischl, DE Vance, AA Adimora
Antimicrobial agents and chemotherapy 2020
Nucleoside analogs as a rich source of antiviral agents active against arthropod-borne flaviviruses
L Eyer, R Nencka, E de Clercq, K Seley-Radtke, D Růžek
Antiviral Chemistry and Chemotherapy 2018
Arbidol (Umifenovir): A Broad-Spectrum Antiviral Drug That Inhibits Medically Important Arthropod-Borne Flaviviruses
J Haviernik, M Štefánik, M Fojtíková, S Kali, N Tordo, I Rudolf, Z Hubálek, L Eyer, D Ruzek
Viruses 2018
Chalcogenozidovudine Derivatives With Antitumor Activity: Comparative Toxicities in Cultured Human Mononuclear Cells
A Ecker, PC Ledur, RS da Silva, DB Leal, OE Rodrigues, D Ardisson-Araújo, EP Waczuk, JB da Rocha, NV Barbosa
Toxicological Sciences 2017
Broad-spectrum agents for flaviviral infections: dengue, Zika and beyond
V Boldescu, MA Behnam, N Vasilakis, CD Klein
Nature Reviews Drug Discovery 2017
Nucleotide Reverse Transcriptase Inhibitors: A Thorough Review, Present Status and Future Perspective as HIV Therapeutics.
Holec AD, Mandal S, Prathipati PK, Destache CJ
Current HIV research 2017
The Medicinal Chemistry of Dengue Virus
MA Behnam, C Nitsche, V Boldescu, CD Klein
Journal of Medicinal Chemistry 2016
A Translational Pharmacology Approach to Predicting Outcomes of Preexposure Prophylaxis Against HIV in Men and Women Using Tenofovir Disoproxil Fumarate With or Without Emtricitabine
ML Cottrell, KH Yang, HM Prince, C Sykes, N White, S Malone, ES Dellon, RD Madanick, NJ Shaheen, MG Hudgens, J Wulff, KB Patterson, JA Nelson, AD Kashuba
The Journal of Infectious Diseases 2016
Exposure to zidovudine adversely affects mitochondrial turnover in primary T cells
ZR Wallace, S Sanderson, AK Simon, L Dorrell
Antiviral Research 2016
Impact of HIV-1 infection pathways on susceptibility to antiviral drugs and on virus spread
K Shimura, P Miyazato, S Oishi, N Fujii, M Matsuoka
Virology 2015
The search for nucleoside/nucleotide analog inhibitors of dengue virus
YL Chen, F Yokokawa, PY Shi
Antiviral Research 2015
SAMHD1 Specifically Affects the Antiviral Potency of Thymidine Analog HIV Reverse Transcriptase Inhibitors
E Ballana, R Badia, G Terradas, J Torres-Torronteras, A Ruiz, E Pauls, E Riveira-Munoz, B Clotet, R Marti, JA Este
Antimicrobial agents and chemotherapy 2014
Depot-Medroxyprogesterone Acetate Does Not Reduce the Prophylactic Efficacy of Emtricitabine and Tenofovir Disoproxil Fumarate in Macaques:
J Radzio, K Hanley, J Mitchell, S Ellis, F Deyounks, L Jenkins, W Heneine, JG García-Lerma
Journal of acquired immune deficiency syndromes (1999) 2014
Pharmacology Lessons From Chemoprophylaxis Studies
M Boffito, A Jackson, D Asboe
Clinical Infectious Diseases 2014
Tenofovir, Emtricitabine Intracellular and Plasma, and Efavirenz Plasma Concentration Decay Following Drug Intake Cessation: Implications for HIV Treatment and Prevention
A Jackson, G Moyle, V Watson, J Tjia, A Ammara, D Back, M Mohabeer, B Gazzard, M Boffito
Journal of acquired immune deficiency syndromes (1999) 2013
Activation of peripheral blood mononuclear cells by dengue virus infection depotentiates balapiravir
YL Chen, NA Ghafar, R Karuna, Y Fu, SP Lim, W Schul, F Gu, M Herve, F Yokohama, G Wang, D Cerny, K Fink, F Blasco, PY Shi
Journal of virology 2013
Ten years of dengue drug discovery: Progress and prospects
SP Lim, QY Wang, CG Noble, YL Chen, H Dong, B Zou, F Yokokawa, S Nilar, P Smith, D Beer, J Lescar, PY Shi
Antiviral Research 2013
Human Immunodeficiency Virus Reverse Transcriptase
S LeGrice, M Gotte
2013
Effect of HIV-1 infection and sex on the cellular pharmacology of the antiretroviral drugs zidovudine and lamivudine
JE Rower, A Meditz, EM Gardner, K Lichtenstein, J Predhomme, LR Bushman, B Klein, JH Zheng, S Mawhinney, PL Anderson
Antimicrobial agents and chemotherapy 2012
Pharmacokinetics of abacavir and its anabolite carbovir triphosphate without and with darunavir/ritonavir or raltegravir in HIV-infected subjects
A Jackson, G Moyle, L Dickinson, D Back, S Khoo, J Taylor, K Gedela, G Abongomera, B Gazzard, M Boffito
Antiviral therapy 2012
Anti-HIV nucleoside drugs: A retrospective view into the future
MK Kukhanova
Molecular Biology 2012
Advances in Mitochondrial Medicine
R Scatena, P Bottoni, B Giardina
Advances in Mitochondrial Medicine 2011
Advances in Mitochondrial Medicine
R Scatena, P Bottoni, B Giardina
Advances in Mitochondrial Medicine 2011
Advances in Mitochondrial Medicine
R Scatena, P Bottoni, B Giardina
Advances in Mitochondrial Medicine 2011
Advances in Mitochondrial Medicine
R Scatena, P Bottoni, B Giardina
Advances in Mitochondrial Medicine 2011
Advances in Mitochondrial Medicine
R Scatena, P Bottoni, B Giardina
Advances in Mitochondrial Medicine 2011
Advances in Mitochondrial Medicine
R Scatena, P Bottoni, B Giardina
Advances in Mitochondrial Medicine 2011
Advances in Mitochondrial Medicine
R Scatena, P Bottoni, B Giardina
Advances in Mitochondrial Medicine 2011
Advances in Mitochondrial Medicine
R Scatena, P Bottoni, B Giardina
Advances in Mitochondrial Medicine 2011
Advances in Mitochondrial Medicine
R Scatena, P Bottoni, B Giardina
Advances in Mitochondrial Medicine 2011
Advances in Mitochondrial Medicine
R Scatena, P Bottoni, B Giardina
Advances in Mitochondrial Medicine 2011
Effect of Nucleoside and Nucleotide Analog Reverse Transcriptase Inhibitors on Cell-Mediated Immune Functions
L Enomoto, PL Anderson, S Li, CL Edelstein, A Weinberg
AIDS Research and Human Retroviruses 2011
The Role of Therapeutic Drug Monitoring in the Management of Patients With Human Immunodeficiency Virus Infection
E Pretorius, H Klinker, B Rosenkranz
Therapeutic Drug Monitoring 2011
Natural Substrate Concentrations Can Modulate the Prophylactic Efficacy of Nucleotide HIV Reverse Transcriptase Inhibitors
JG Garcia-Lerma, W Aung, M Cong, Q Zheng, AS Youngpairoj, J Mitchell, A Holder, A Martin, S Kuklenyik, W Luo, CY Lin, DL Hanson, E Kersh, CP Pau, AS Ray, JF Rooney, WA Lee, W Heneine
Journal of virology 2011
Pre-steady-state kinetic analysis of the incorporation of anti-HIV nucleotide analogs catalyzed by human X- and Y-family DNA polymerases
JA Brown, LR Pack, JD Fowler, Z Suo
Antimicrobial agents and chemotherapy 2010
Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 years after zidovudine
T Cihlar, AS Ray
Antiviral Research 2010
Development of a stochastic model for the efficacy of NRTIs using known mechanisms of action
S Khalili, JM Monaco, A Armaou
Journal of Theoretical Biology 2010
Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases
VG Fowler, WM Scheld, AS Bayer
Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases 2010
Decomposition of 3′-azido-2′,3′-dideoxythymidine 5′-monophosphate (AZTMP) prodrugs in biological media studied by on-line solid-phase extraction coupled to liquid chromatography mass spectrometry
I Lefebvre, T Beltran, S Peyrottes, C Périgaud
Biomedical Chromatography 2009
Lead optimization and structure-based design of potent and bioavailable deoxycytidine kinase inhibitors
TC Jessop, JE Tarver, M Carlsen, A Xu, JP Healy, A Heim-Riether, Q Fu, JA Taylor, DJ Augeri, M Shen, TR Stouch, RV Swanson, LW Tari, M Hunter, I Hoffman, PE Keyes, XC Yu, M Miranda, Q Liu, JC Swaffield, SD Kimball, A Nouraldeen, AG Wilson, AM Foushee, K Jhaver, R Finch, S Anderson, T Oravecz, KG Carson
Bioorganic & Medicinal Chemistry Letters 2009
Effector caspase activation, in the absence of a conspicuous apoptosis induction, in mononuclear cells treated with azidothymidine
C Matteucci, A Minutolo, E Balestrieri, A Ascolani, S Grelli, B Macchi, A Mastino
Pharmacological research : the official journal of the Italian Pharmacological Society 2009
Anti-Human Immunodeficiency Virus Activity, Cross-Resistance, Cytotoxicity, and Intracellular Pharmacology of the 3′-Azido-2′,3′-Dideoxypurine Nucleosides
N Sluis-Cremer, D Koontz, L Bassit, BI Hernandez-Santiago, M Detorio, KL Rapp, F Amblard, L Bondada, J Grier, SJ Coats, RF Schinazi, JW Mellors
Antimicrobial agents and chemotherapy 2009
DNA polymerases as therapeutic targets
AJ Berdis
Biochemistry 2008
Cytokine and sex hormone effects on zidovudine- and lamivudine-triphosphate concentrations in vitro
PL Anderson, T King, JH Zheng, S MaWhinney
The Journal of antimicrobial chemotherapy 2008
Differential extracellular and intracellular concentrations of zidovudine and lamivudine in semen and plasma of HIV-1-infected men
JB Dumond, YS Reddy, L Troiani, JF Rodriguez, AS Bridges, SA Fiscus, GJ Yuen, MS Cohen, AD Kashuba
Journal of acquired immune deficiency syndromes (1999) 2008
Recent developments in the clinical pharmacology of anti-HIV nucleoside analogs
PL Anderson
Current Opinion in HIV and AIDS 2008
Simultaneous determination of endogenous deoxynucleotides and phosphorylated nucleoside reverse transcriptase inhibitors in peripheral blood mononuclear cells using ion-pair liquid chromatography coupled to mass spectrometry
L Coulier, JJ van Kampen, R Groot, HW Gerritsen, RC Bas, WD van Dongen, LP Brüll, TM Luider
PROTEOMICS - CLINICAL APPLICATIONS 2008
Concentrations of zidovudine- and lamivudine-triphosphate according to cell type in HIV-seronegative adults
PL Anderson, JH Zheng, T King, LR Bushman, J Predhomme, A Meditz, J Gerber, CV Fletcher
AIDS 2007
HIV-1 reverse transcriptase inhibitors
Y Safadi, V Vivet-Boudou, R Marquet
Applied Microbiology and Biotechnology 2007
Comparative evaluation of the activity of antivirals towards feline immunodeficiency virus in different cell culture systems
FJ der Meer, NM Schuurman, J Balzarini, HF Egberink
Antiviral Research 2007
Prodrugs
VJ Stella, RT Borchardt, MJ Hageman, R Oliyai, H Maag, JW Tilley
2007
Human Immunodeficiency Virus Type 1: Resistance to Nucleoside Analogues and Replicative Capacity in Primary Human Macrophages
D Perez-Bercoff, S Wurtzer, S Compain, H Benech, F Clavel
Journal of virology 2007
Activity against Human Immunodeficiency Virus Type 1, Intracellular Metabolism, and Effects on Human DNA Polymerases of 4′-Ethynyl-2-Fluoro-2′-Deoxyadenosine
H Nakata, M Amano, Y Koh, E Kodama, G Yang, CM Bailey, S Kohgo, H Hayakawa, M Matsuoka, KS Anderson, YC Cheng, H Mitsuya
Antimicrobial agents and chemotherapy 2007
Evidence and Possible Consequences of the Phosphorylation of Nucleoside Reverse Transcriptase Inhibitors in Human Red Blood Cells
L Durand-Gasselin, DD Silva, H Benech, A Pruvost, J Grassi
Antimicrobial agents and chemotherapy 2007
Nucleoside and Nucleotide Reverse Transcriptase Inhibitors in Children:
C Giaquinto, O Rampon, M Penazzato, F Fregonese, AD Rossi, R DElia
Clinical Drug Investigation 2007
R5 Variants of Human Immunodeficiency Virus Type 1 Preferentially Infect CD62L − CD4 + T Cells and Are Potentially Resistant to Nucleoside Reverse Transcriptase Inhibitors
F Gondois-Rey, A Biancotto, MA Fernandez, L Bettendroffer, J Blazkova, K Trejbalova, M Pion, I Hirsch
Journal of virology 2006
Reverse Transcriptase Inhibitors in HIV/AIDS Therapy
V St.Georgiev, G Skowron, R Ogden, JM Lange
2006
Thymidine kinase and deoxycytidine kinase activity in mononuclear cells from antiretroviral-naive HIV-infected patients
O Turriziani, O Butera, N Gianotti, SG Parisi, R Mazzi, E Girardi, G Iaiani, L Antonelli, A Lazzarin, G Antonelli
AIDS 2005
Antiviral Therapies in Children: Has Their Time Arrived?
DW Kimberlin
Pediatric Clinics of North America 2005
Therapeutic Drug Monitoring: Role for a Pharmacist in Multidisciplinary Antiretroviral Management
JC Slish, LM Catanzaro, O Okusanya, LM Demeter, M Albrecht, R Difrancesco, GD Morse
Journal of Pharmacy Practice 2005
Pharmacokinetics of Antiretroviral Therapy in HIV-1-Infected Children:
PL Fraaij, JJ van Kampen, DM Burger, R de Groot
Clinical Pharmacokinetics 2005
Effect of Cell Cycle Arrest on the Activity of Nucleoside Analogues against Human Immunodeficiency Virus Type 1
S Wurtzer, S Compain, H Benech, AJ Hance, F Clavel
Journal of virology 2005
Differential effects of R5 and X4 human immunodeficiency virus type 1 infection on CD4+ cell proliferation and activation
CP Locher, SA Witt, R Kassel, NL Dowell, S Fujimura, JA Levy
Journal of General Virology 2005
Zidovudine, lamivudine, and abacavir have different effects on resting cells infected with human immunodeficiency virus in vitro
J Saavedra-Lozano, CC McCoig, Y Cao, ES Vitetta, O Ramilo
Antimicrobial agents and chemotherapy 2004
A new method for analysis of AZT-triphosphate and nucleotide-triphosphates
JJ van Kampen, PL Fraaij, V Hira, AM van Rossum, NG Hartwig, R Groot, TM Luider
Biochemical and Biophysical Research Communications 2004
Therapeutic Drug Monitoring in Children with HIV/AIDS
PL Fraaij, N Rakhmanina, DM Burger, R Groot
Therapeutic Drug Monitoring 2004
Activity, Safety, and Immunological Effects of Hydroxyurea Added to Didanosine in Antiretroviral-Naive and Experienced HIV Type 1-Infected Subjects: A Randomized, Placebo-Controlled Trial, ACTG 307
I Frank, RJ Bosch, S Fiscus, F Valentine, C Flexner, Y Segal, P Ruan, R Gulick, K Wood, S Estep, L Fox, T Nevin, M Stevens, JJ Eron
AIDS Research and Human Retroviruses 2004
The Cellular Pharmacology of Nucleoside‐ and Nucleotide‐Analogue Reverse‐Transcriptase Inhibitors and Its Relationship to Clinical Toxicities
PL Anderson, TN Kakuda, KA Lichtenstein
Clinical Infectious Diseases 2004
Pharmacokinetic Properties of Nucleoside/Nucleotide Reverse Transcriptase Inhibitors:
PJ Piliero
Journal of acquired immune deficiency syndromes (1999) 2004
Combination Therapy of AIDS
ED Clercq, AM Vandamme
2004
Real Versus Virtual Phenotype to Guide Treatment in Heavily Pretreated Patients: 48-Week Follow-Up of the Genotipo-Fenotipo di Resistenza (GenPheRex) Trial
F Mazzotta, SL Caputo, C Torti, C Tinelli, P Pierotti, F Castelli, A Lazzarin, G Angarano, R Maserati, N Gianotti, N Ladisa, E Quiros-Roldan, AR Rinehart, G Carosi
JAIDS Journal of Acquired Immune Deficiency Syndromes 2003
Investigation of nucleoside analogs with anti-HIV activity
M Arissawa, CA Taft, J Felcman
International Journal of Quantum Chemistry 2003
Replication Kinetics for Divergent Type 1 Human Immunodeficiency Viruses Using Quantitative SYBR Green I Real-Time Polymerase Chain Reaction
JG Victoria, DJ Lee, BR McDougall, WE Robinson
AIDS Research and Human Retroviruses 2003
Pharmacodynamics and clinical use of anti-HIV drugs
SL Preston, PJ Piliero, GL Drusano
Infectious Disease Clinics of North America 2003
PHARMACOLOGICAL AND BIOLOGICAL ASPECTS OF BASIC RESEARCH ON NUCLEOSIDE-BASED REVERSE TRANSCRIPTASE INHIBITORS
B Macchi, A Mastino
Pharmacological Research 2002
Immunomodulatory effect of zidovudine (ZDV) on cytotoxic T lymphocytes previously exposed to ZDV
S Francke, CG Orosz, J Hsu, LE Mathes
Antimicrobial agents and chemotherapy 2002
Genotypic testing for human immunodeficiency virus type 1 drug resistance
RW Shafer
Clinical microbiology reviews 2002
HIV-1 drug resistance: can we overcome?
BG Brenner, MA Wainberg, D Turner
Expert Opinion on Biological Therapy 2002
Activity of Reverse Transcriptase Inhibitors in Monocyte-Derived Dendritic Cells: A Possiblein VitroModel for Postexposure Prophylaxis of Sexual HIV Transmission
YV Herrewege, L Penne, C Vereecken, K Fransen, G der Groen, L Kestens, J Balzarini, G Vanham
AIDS Research and Human Retroviruses 2002
Antiretroviral pharmacokinetics in the paediatric population: a review.
King JR, Kimberlin DW, Aldrovandi GM, Acosta EP
Clinical Pharmacokinetics 2002
Influence of prior exposure to zidovudine on stavudine phosphorylation in vivo and ex vivo
PG Hoggard, SD Sales, D Phiboonbanakit, J Lloyd, BA Maher, SH Khoo, E Wilkins, P Carey, CA Hart, DJ Back
Antimicrobial agents and chemotherapy 2001
Mitochondrial toxicity associated with nucleoside reverse transcriptase inhibitor therapy
CM Shikuma, B Shiramizu
Current Infectious Disease Reports 2001
Testing the reverse transcriptase model of somatic mutation
SZ Sack, PD Bardwell, MD Scharff
Molecular Immunology 2001
Phosphorylation of Nucleoside Analog Antiretrovirals: A Review for Clinicians
DS Stein, KH Moore
Pharmacotherapy 2001
A Guide to HIV-1 Reverse Transcriptase and Protease Sequencing for Drug Resistance Studies
RW Shafer, K Dupnik, MA Winters, SH Eshleman
HIV sequence compendium 2001
Zidovudine Phosphorylation and Mitochondrial Toxicity in Vitro
SD Sales, PG Hoggard, D Sunderland, S Khoo, CA Hart, DJ Back
Toxicology and Applied Pharmacology 2001
Phase I/II dose escalation and randomized withdrawal study with add-on azodicarbonamide in patients failing on current antiretroviral therapy:
FD Goebel, R Hemmer, JC Schmit, JR Bogner, E Clercq, M Witvrouw, C Pannecouque, R Valeyev, M Vandevelde, H Margery, JP Tassignon
AIDS 2001
Plasma Drug Levels Compared with DNA Incorporation of 3′-azido-3′-Deoxythymidine (AZT) in Adult Cynomolgus (Macaca fascicularis) Monkeys
OA Olivero, MK Reddy, SM Pietras, MC Poirier
Experimental biology and medicine (Maywood, N.J.) 2001
Thymidine Kinase-Independent Intracellular Delivery of Bioactive Nucleotides by Aryl Phosphate Derivatives of Bromo-Methoxy Zidovudine (Compounds WHI-05 and WHI-07) in Normal Human Female Genital Tract Epithelial Cells and Sperm1
OJ DCruz, TK Venkatachalam, FM Uckun
Biology of reproduction 2001
Atlas of AIDS
GL Mandell, D Mildvan
2001
Mitochondrial Toxicity Associated with Nucleoside Reverse Transcriptase Inhibitor Therapy.
Shikuma CM, Shiramizu B
Current Infectious Disease Reports 2001
The Genetic Basis of HIV-1 Resistance to Reverse Transcriptase and Protease Inhibitors
RW Shafer, R Kantor, MJ Gonzales
AIDS reviews 2000
Effect of two different combinations of antiretrovirals (AZT+ddI and AZT+3TC) on cytokine production and apoptosis in asymptomatic HIV infection
S Piconi, D Trabattoni, ML Fusi, F Milazzo, LP Dix, G Rizzardini, F Colombo, D Bray, M Clerici
Antiviral Research 2000
Antileukemic activity and mechanism of action of cordycepin against terminal deoxynucleotidyl transferase-positive (TdT+) leukemic cells
E Kodama
Biochemical Pharmacology 2000
Simultaneous quantitation of the 5′-triphosphate metabolites of zidovudine, lamivudine, and stavudine in peripheral mononuclear blood cells of HIV infected patients by high-performance liquid chromatography tandem mass spectrometry
JD Moore, G Valette, A Darque, XJ Zhou, JP Sommadossi
Journal of the American Society for Mass Spectrometry 2000
Antiviral Resistance of Biologic HIV-2 Clones Obtained From Individuals on Nucleoside Reverse Transcriptase Inhibitor Therapy
ME van der Ende, C Guillon, PH Boers, TD Ly, RA Gruters, AD Osterhaus, M Schutten
JAIDS Journal of Acquired Immune Deficiency Syndromes 2000
Phase II Placebo-Controlled Trial of Fozivudine Tidoxil for HIV Infection: Pharmacokinetics, Tolerability, and Efficacy
PM Girard, PS Pegram, B Diquet, R Anderson, F Raffi, R Tubiana, D Sereni, D Boerner
JAIDS Journal of Acquired Immune Deficiency Syndromes 2000
Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity
TN Kakuda
Clinical Therapeutics 2000
Potentiation of The Anti-HIV Activity of Zalcitabine and Lamivudine by a CTP Synthase Inhibitor, 3-Deazauridine
WY Gao, DG Johns, H Mitsuya
Nucleosides Nucleotides & Nucleic Acids 2000
Simultaneous determination of zidovudine and its monophosphate in mouse plasma and peripheral red blood cells by high-performance liquid chromatography
X Tan, FD Boudinot
Journal of Chromatography B: Biomedical Sciences and Applications 2000
AIDS-Related Cancers and Their Treatment
S Miles
AIDS-Related Cancers and Their Treatment 2000
Zidovudine triphosphate and lamivudine triphosphate concentration–response relationships in HIV-infected persons:
CV Fletcher, SP Kawle, TN Kakuda, PL Anderson, D Weller, LR Bushman, RC Brundage, RP Remmel
AIDS 2000
A randomized, dose-finding study with didanosine plus stavudine versus didanosine alone in antiviral-naive, HIV-infected Thai patients:
K Ruxrungtham, ED Kroon, C Ungsedhapand, S Teeratakulpisarn, S Ubolyam, S Buranapraditkun, R Leeuwen, GJ Weverling, C Kunanusont, JM Lange, DA Cooper, P Phanuphak
AIDS 2000
Pharmacokinetics of Bis(t-butyl-SATE)-AZTMP, a Bispivaloylthioethyl Prodrug for Intracellular Delivery of Zidovudine Monophosphate, in Mice
X Tan, FD Boudinot, CK Chu, D Egron, C Perigaud, G Gosselin, JL Imbach
Antiviral Chemistry & Chemotherapy 2000
Diminished Human Immunodeficiency Virus Type 1 Reverse Transcription and Nuclear Transport in Primary Macrophages Arrested in Early G 1 Phase of the Cell Cycle
NA Kootstra, BM Zwart, H Schuitemaker
Journal of virology 2000
Simultaneous quantitation of the 5'-triphosphate metabolites of zidovudine, lamivudine, and stavudine in peripheral mononuclear blood cells of HIV infected patients by high-performance liquid chromatography tandem mass spectrometry.
Moore JD, Valette G, Darque A, Zhou XJ, Sommadossi JP
Journal of the American Society for Mass Spectrometry 2000
Quantitation of intracellular triphosphate of emtricitabine in peripheral blood mononuclear cells from human immunodeficiency virus-infected patients
A Darque, G Valette, F Rousseau, LH Wang, JP Sommadossi, XJ Zhou
Antimicrobial agents and chemotherapy 1999
Reverse transcriptase inhibitors can selectively block the synthesis of differently sized viral DNA transcripts in cells acutely infected with human immunodeficiency virus type 1
Y Quan, L Rong, C Liang, MA Wainberg
Journal of virology 1999
Use of a non-adherent cell culture system for testing the effect of 2′,3′-dideoxyinosine againstCryptosporidium parvum
P Lawton, C Hejl, ME Sarciron, R Mancassola, M Naciri, AF Petavy
FEMS Microbiology Letters 1999
Highly active antiretroviral therapy (Haart) for the treatment of infection with human immunodeficiency virus type 1
R Shafer, D Vuitton
Biomedecine & Pharmacotherapy 1999
Safety and Antiretroviral Effects of Combined Didanosine and Stavudine Therapy in HIV-Infected Individuals With CD4 Counts of 200 to 500 cells/mm3
RB Pollard, D Peterson, D Hardy, J Pottage, RL Murphy, J Gathe, G Beall, V Rutkievicz, L Reynolds, AP Cross, LM Dunkle
Journal of Acquired Immune Deficiency Syndromes 1999
Transport, metabolism and elimination mechanisms of anti-HIV agents
X Li, WK Chan
Advanced Drug Delivery Reviews 1999
Intracellular Activation of 2',3'-Dideoxyinosine and Drug Interactions in Vitro
S Kewn, PG Hoggard, JS Henry-Mowatt, GJ Veal, SD Sales, MG Barry, DJ Back
AIDS Research and Human Retroviruses 1999
Intracellular Phosphorylation of Zidovudine in an In Vitro Hollow Fiber Model
KZ Rana, MN Dudley
Pharmacotherapy 1999
Synthesis of a non-hydrolyzable AZT-triphosphate analogue designed for the production of anti-AZT-TP antibodies
T Brossette, A Valleix, L Goujon, C Cre´minon, J Grassi, C Mioskowski, L Lebeau
Tetrahedron Letters 1999
HIV and the New Viruses
S McAdam, F Gotch
HIV and the New Viruses 1999
Advances in Antiviral Drug Design
MN Arimilli, JP Dougherty, KC Cundy, N Bischofberger
Advances in Antiviral Drug Design 1999
Early Steps of Replication of Moloney Murine Leukemia Virus in Resting Lymphocytes
L Piéroni, P Bouillé, C Auclair, JJ Guillosson, J Nafziger
Virology 1999
Nonproductive Human Immunodeficiency Virus Type 1 Infection in Nucleoside-Treated G 0 Lymphocytes
YD Korin, JA Zack
Journal of virology 1999
Synergistic inhibition of HIV-1 by an antisense oligonucleotide and nucleoside analog reverse transcriptase inhibitors
GJ Veal, S Agrawal, RA Byrn
Antiviral Research 1998
Effect of Ribavirin on Zidovudine Efficacy and Toxicityin Vitro: A Concentration-Dependent Interaction
S Sim, P Hoggard, S Sales, D Phiboonbanakit, C Hart, D Back
AIDS Research and Human Retroviruses 1998
Efficient inhibition of both syncytium-inducing and non-syncytium-inducing wild-type HIV-1 by lamivudine in vivo
AB van Wout, LJ Ran, M Nijhuis, JM Tijnagel, T Groot, R Leeuwen, CA Boucher, H Schuitemaker, R Schuurman
AIDS 1998
Mechanisms of clinical resistance by HIV-I variants to zidovudine and the paradox of reverse transcriptase sensitivity
EJ Arts, ME Quiñones-Mateu, JL Albright
Drug Resistance Updates 1998
High-Performance Liquid Chromatographic Method for the Determination of Intracellular dTTP Pools
D Siccardi, AD Ranieri, A Jayewardene, JG Gambertoglio
Journal of Liquid Chromatography & Related Technologies 1998
Monitoring of intracellular levels of 5′-monophosphate-AZT using an enzyme immunoassay
L Goujon, T Brossette, N Dereudre-Bosquet, C Creminon, P Clayette, D Dormont, C Mioskowski, L Lebeau, J Grassi
Journal of Immunological Methods 1998
Role of the M2 subunit of ribonucleotide reductase in regulation by hydroxyurea of the activity of the anti-HIV-1 agent 2',3'-dideoxyinosine
W Y Gao, B S Zhou, D G Johns, H Mitsuya, Y Yen
Biochemical Pharmacology 1998
Intracellular Nucleotides of (−)-2′,3′-Deoxy-3′-Thiacytidine in Peripheral Blood Mononuclear Cells of a Patient Infected with Human Immunodeficiency Virus
C Solas, YF Li, MY Xie, JP Sommadossi, XJ Zhou
Antimicrobial agents and chemotherapy 1998
Safety, Pharmacokinetics, and Antiretroviral Activity of Intravenous 9-[2-( R )-(Phosphonomethoxy)propyl]adenine, a Novel Anti-Human Immunodeficiency Virus (HIV) Therapy, in HIV-Infected Adults
SG Deeks, P Barditch-Crovo, PS Lietman, F Hwang, KC Cundy, JF Rooney, NS Hellmann, S Safrin, JO Kahn
Antimicrobial agents and chemotherapy 1998
Intracellular phosphorylation of zidovudine (ZDV) and other nucleoside reverse transcriptase inhibitors (RTI) used for human immunodeficiency virus (HIV) infection.
Peter K, Gambertoglio JG
Pharmaceutical Research 1998
Selective inhibition of syncytium-inducing and nonsyncytium-inducing HIV-1 variants in individuals receiving didanosine or zidovudine, respectively
AB Wout, LJ Ran, MD de Jong, M Bakker, R Leeuwen, DW Notermans, AE Loeliger, F Wolf, SA Danner, P Reiss, CA Boucher, JM Lange, H Schuitemaker
Journal of Clinical Investigation 1997
In vitro induction of human immunodeficiency virus type 1 variants resistant to 2'-beta-Fluoro-2',3'-dideoxyadenosine
M Tanaka, RV Srinivas, T Ueno, MF Kavlick, FK Hui, A Fridland, JS Driscoll, H Mitsuya
Antimicrobial agents and chemotherapy 1997
Effects of RP 55778, a tumor necrosis factor alpha synthesis inhibitor, on antiviral activity of dideoxynucleosides
P Clayette, N Dereuddre-Bosquet, M Martin, P Fretier, D Dormont
Antimicrobial agents and chemotherapy 1997
Increased activation of the combination of 3'-azido-3'-deoxythymidine and 2'-deoxy-3'-thiacytidine in the presence of hydroxyurea
S Palmer, S Cox
Antimicrobial agents and chemotherapy 1997
Effect of combination therapy with zidovudine and didanosine on neuropsychological functioning in patients with symptomatic HIV disease
P Brouwers, M Hendricks, JA Lietzau, JM Pluda, H Mitsuya, S Broder, R Yarchoan
AIDS 1997
Lamivudine (3TC) phosphorylation and drug interactions in vitro
S Kewn, GJ Veal, PG Hoggard, MG Barry, DJ Back
Biochemical Pharmacology 1997
2′-Fluoro-2′,3′-Dideoxyarabinosyladenine (F-ddA): Activity against Drug-Resistant Human Immunodeficiency Virus Strains and Clades A-E
JS Driscoll, DL Mayers, JP Bader, OS Weislow, DG Johns, RW Buckheit
Antiviral Chemistry & Chemotherapy 1997
Zalcitabine. An update of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of HIV infection.
Adkins JC, Peters DH, Faulds D
Drugs 1997
Inhibition of Murine AIDS by Combination of AZT and Dideoxycytidine 5'-Triphosphate
A Fraternale, A Casabianca, L Rossi, L Chiarantini, G Brandi, G Aluigi, GF Schiavano, M Magnani
Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 1996
Use of standardized SCID-hu Thy/Liv mouse model for preclinical efficacy testing of anti-human immunodeficiency virus type 1 compounds
L Rabin, M Hincenbergs, MB Moreno, S Warren, V Linquist, R Datema, B Charpiot, J Seifert, H Kaneshima, JM McCune
Antimicrobial agents and chemotherapy 1996
Mechanisms of nucleoside analog antiviral activity and resistance during human immunodeficiency virus reverse transcription
EJ Arts, MA Wainberg
Antimicrobial agents and chemotherapy 1996
Comparative kinetic analyses of interaction of inhibitors with Rauscher murine leukemia virus and human immunodeficiency virus reverse transcriptases
JM Cherrington, MD Fuller, AS Mulato, SJ Allen, SC Kunder, MA Ussery, Z Lesnikowski, RF Schinazi, JP Sommadossi, MS Chen
Antimicrobial agents and chemotherapy 1996
In vitro selection and molecular characterization of human immunodeficiency virus type 1 with reduced sensitivity to 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA)
A Fol, KM Sogocio, B Anderson, M Kavlick, MW Saville, MA Wainberg, Z Gu, JM Cherrington, H Mitsuya, R Yarchoan
Antiviral Research 1996
Antiviral activities of nucleotide heterodimers against human immunodeficiency virus type 1 in vitro
K Ijichi, M Fujiwara, K Mori, M Morozumi, H Machida, S Shigeta, K Konno, T Yokota, M Baba
Antiviral Research 1996
Determination of HIV-1 susceptibility to reverse transcriptase (RT) inhibitors by a quantitative cell-free RT assay
R Greene
Clinical and Diagnostic Virology 1996
A Randomized Trial (ISS 901) of Switching to Didanosine Versus Continued Zidovudine after the Diagnosis of AIDS
S Vella, M Floridia, LG Dally, C Tomino, V Fragola, LE Weimer, F Milazzo, F Mazzotta, M Moroni, G Pastore, G Scalise, A Sinicco, L Ortona, BD Rienzo, F Dianzani
Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 1996
Les anti-rétroviraux
J Durant, P Dellamonica
Médecine et Maladies Infectieuses 1996
Anti-human immunodeficiency virus type 1 activities of dideoxynucleoside phosphotriester derivatives in primary monocytes/macrophages
C Thumann-Schweitzer, G Gosselin, C Périgaud, S Benzaria, JL Girardet, I Lefebvre, JL Imbach, A Kirn, AM Aubertin
Research in Virology 1996
Drug Evaluation: Anti-infectives: Saquinavir: A review of its development, pharmacological properties and clinical use
G Moyle
Expert Opinion on Investigational Drugs 1996
Intracellular Metabolism of 3′-Azido-3′-Deoxythymidine in the Presence of Ganciclovir or Foscarnet
S Palmer, H Rasmussen, J Harmenberg, S Cox
Antiviral Chemistry & Chemotherapy 1996
Drug Resistance
WN Hait
1996
Antiviral Chemotherapy 4
J Mills, PA Volberding, L Corey
1996
Effects of 3'-deoxynucleoside 5'-triphosphate concentrations on chain termination by nucleoside analogs during human immunodeficiency virus type 1 reverse transcription of minus-strand strong-stop DNA
EJ Arts, JP Marois, Z Gu, SF Grice, MA Wainberg
Journal of virology 1996
Current knowledge and future prospects for the use of HIV protease inhibitors.
Moyle G, Gazzard B
Drugs 1996
HIV-1 chemotherapy and drug resistance
R Daquila
Clinical and Diagnostic Virology 1995
Comparative analysis of anti-human immunodeficiency virus type 1 activities of dideoxynucleoside analogs in resting and activated peripheral blood mononuclear cells
T Shirasaka, S Chokekijchai, A Yamada, G Gosselin, JL Imbach, H Mitsuya
Antimicrobial agents and chemotherapy 1995
Sanctuary growth of human immunodeficiency virus in the presence of 3'-azido-3'-deoxythymidine
DJ Medina, PP Tung, MB Lerner-Tung, CJ Nelson, JW Mellors, RK Strair
Journal of virology 1995
Disparate actions of hydroxyurea in potentiation of purine and pyrimidine 2',3'-dideoxynucleoside activities against replication of human immunodeficiency virus
WY Gao, DG Johns, S Chokekuchai, H Mitsuya
Proceedings of the National Academy of Sciences 1995
Drug interactions with zidovudine phosphorylation in vitro
PG Hoggard, GJ Veal, MJ Wild, MG Barry, DJ Back
Antimicrobial agents and chemotherapy 1995
Minireview: nucleotide prodrugs
RJ Jones, N Bischofberger
Antiviral Research 1995
Aromatic amino acid phosphoramidate di- and triesters of 3′-azido-3′-deoxythymidine (AZT) are non-toxic inhibitors of HIV-1 replication
CR Wagner, EJ McIntee, RF Schinazi, TW Abraham
Bioorganic & Medicinal Chemistry Letters 1995
Development of a Human Thymic Organ Culture Model for the Study of HIV Pathogenesis
ML Bonyhadi, L Su, J Auten, JO McCUNE, H Kaneshima
AIDS Research and Human Retroviruses 1995
In vitro anti-HIV-1 activity of HIV protease inhibitor KNI-272 in resting and activated cells: implications for its combined use with AZT or ddI
S Chokekijchai, T Shirasaka, JN Weinstein, H Mitsuya
Antiviral Research 1995
Treatment with Lamivudine, Zidovudine, or Both in HIV-Positive Patients with 200 to 500 CD4+ Cells per Cubic Millimeter
JJ Eron, SL Benoit, J Jemsek, RD MacArthur, J Santana, JB Quinn, DR Kuritzkes, MA Fallon, M Rubin
New England Journal of Medicine 1995
Metabolism of zidovudine
GJ Veal, DJ Back
General Pharmacology: The Vascular System 1995
Zalcitabine (ddC) Phosphorylation and Drug Interactions
GJ Veal, MG Barry, DJ Back
Antiviral Chemistry & Chemotherapy 1995
Host Cell Dependence of Human Immunodeficiency Virus Type-1 Drug Resistance Profiles and Tissue Culture Selection Patterns
H Salomon, Z Gu, Q Gao, K Nagai, J Hiscott, MA Wainberg
Antiviral Chemistry & Chemotherapy 1995
T-lymphocytes from AIDS Patients Are Unable to Synthesize Ribonucleotides de Novo in Response to Mitogenic Stimulation
M Bofill, LD Fairbanks, K Ruckemann, M Lipman, HA Simmonds
The Journal of biological chemistry 1995
Pharmacokinetic Optimisation of Antiretroviral Therapy in Patients with HIV Infection:
BN Stretcher
Clinical Pharmacokinetics 1995
Dideoxynucleoside resistance emerges with prolonged zidovudine monotherapy. The RV43 Study Group
DL Mayers, AJ Japour, JM Arduino, SM Hammer, R Reichman, KF Wagner, R Chung, J Lane, CS Crumpacker, GX McLeod
Antimicrobial agents and chemotherapy 1994
Alternating versus continuous drug regimens in combination chemotherapy of human immunodeficiency virus type 1 infection in vitro
T Mazzulli, S Rusconi, DP Merrill, RT D'Aquila, M Moonis, TC Chou, MS Hirsch
Antimicrobial agents and chemotherapy 1994
Synergistic anti-human immunodeficiency virus type 1 effect of hydroxamate compounds with 2',3'-dideoxyinosine in infected resting human lymphocytes
SD Malley, JM Grange, F Hamedi-Sangsari, JR Vila
Proceedings of the National Academy of Sciences 1994
Effects of dideoxyinosine and dideoxycytidine on the intracellular phosphorylation of zidovudine in human mononuclear cells
GJ Veal, MJ Wild, MG Barry, DJ Back
British Journal of Clinical Pharmacology 1994
Combinative interactions of a human immunodeficiency virus (HIV) Tat antagonist with HIV reverse transcriptase inhibitors and an HIV protease inhibitor
EV Connell, MC Hsu, DD Richman
Antimicrobial agents and chemotherapy 1994
Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy
DD Richman, D Havlir, J Corbeil, D Looney, C Ignacio, SA Spector, J Sullivan, S Cheeseman, K Barringer, D Pauletti
Journal of virology 1994
Comparison of the efficacy of AZT and PMEA treatment against acute SIVmne infection in macaques
CC Tsai, KE Follis, R Grant, A Sabo, R Nolte, C Bartz, N Bischofberger, R Benveniste
Journal of Medical Primatology 1994
Chemistry and Anti-HIV Activity of 2′-β-Fluoro-2′,3′-dideoxyguanosine
H Ford, JS Driscoll, M Siddiqui, JA Kelley, H Mitsuya, T Shirasaka, DG Johns, VE Marquez
Nucleosides and Nucleotides 1994
In vitro studies of the toxicity of nucleoside analogues used in the treatment of HIV infection
OP Flint
Toxicology in Vitro 1994
Equal inhibition of the replication of human immunodeficiency virus in human T-cell culture by ddA BIS(SATE)phosphotriester and 3′-azido-2′,3′-dideoxythymidine
C Pericaud, AM Aubertin, S Benzaria, H Pelicano, JL Girardet, G Maury, G Gosselin, A Kirn, JL Imbach
Biochemical Pharmacology 1994
Enzymatic phosphorylation and pyrophosphorylation of 2',3'-dideoxyadenosine-5'-monophosphate, a key metabolite in the pathway for activation of the anti-HIV (human immunodeficiency virus) agent 2',3'-dideoxyinosine
JF Navé, A Eschbach, D Wolff-Kugel, S Halazy, J Balzarini
Biochemical Pharmacology 1994
Intracellular Metabolism of 3′-azido-3′-deoxythymidine and 2′,3′-dideoxyinosine in Combination in the Absence and Presence of Ribavirin
S Palmer, S Cox
Antiviral Chemistry & Chemotherapy 1994
Divergent anti-human immunodeficiency virus activity and anabolic phosphorylation of 2‘,3‘-dideoxynucleoside analogs in resting and activated human cells
WY Gao, R Agbaria, JS Driscoll, H Mitsuya
The Journal of biological chemistry 1994
Present Status and Future Prospects for HIV Therapies
MI Johnston, DF Hoth
Science 1993

← Previous 1 2 3 … 7 8 Next →

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Referenced in 1 policy sources
Referenced in 5 patents
34 readers on Mendeley
See more details